Provided is an indicator for a measurement device for measuring skin conditions of a human, which can display degrees of progress in at least two kinds of states. The includes: a case; a measurement auxiliary unit slidably supported by the case; and a sensor part slidably supported by the measurement auxiliary unit. The indicator has: a window part formed in a side surface portion of the case; a first display part slidably supported inside the window part and connected to the measurement auxiliary unit; and a second display part slidably supported inside the window part and connected to the sensor part. A slide direction and slide amount of the first display part coincides with a slide direction and slide amount of the measurement auxiliary unit, and a slide direction and slide amount of the second display part coincide with a slide direction and slide amount of the sensor part.
NATIONAL UNIVERSITY CORPORATION UNIVERSITY OF TOYAMA (Japan)
MARUHO CO., LTD. (Japan)
Inventor
Izuhara Kenji
Nunomura Satoshi
Nanri Yasuhiro
Kitajima Isao
Uta Daisuke
Shigeno Tomomi
Tobetto Kenji
Ishihata Akihiro
Abstract
Provided is a technique for preventing or treating a periostin-mediated disease and pruritus associated with the disease. The present invention relates to, for example, an external preparation for preventing or treating a periostin-mediated disease or pruritus associated with the disease, said preparation containing a specific periostin receptor antagonist as an active ingredient.
Provided is a benzoyl peroxide-containing composition that has smaller change in viscosity over time and can be easily removed from the skin. This skin composition comprises: (A) benzoyl peroxide; (B) an acrylamide-(sodium acryloyldimethyltaurate) copolymer; (C) a surfactant comprising at least one selected from the group consisting of (c1) a combination of sodium lauroyl sarcosinate and at least one anionic surfactant and/or nonionic surfactant, (c2) at least one anionic surfactant selected from the group consisting of sodium lauryl sulfate, polyoxyethylene alkyl ether phosphates, polyoxyethylene alkyl ether sulfates, and sodium lauroyl glutamate, and (c3) a combination of sodium oleate and at least one anionic surfactant and/or nonionic surfactant; and (D) at least one water-based solvent selected from among water and a water-soluble solvent. The skin composition is used by being applied to an affected area of the skin, left to stand for a predetermined time, and subsequently removed from the affected area.
A61K 8/44 - Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfurSalts, esters or N-acylated derivatives thereof
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
A61K 31/327 - Peroxy compounds, e.g. hydroperoxides, peroxides, peroxy acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
The present disclosure provides a pharmaceutical composition which comprises an anti-IL-31 receptor A antibody as an active ingredient thereof, and which is for the treatment of perforating dermatosis.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
It is an object of the present invention to provide a film-forming composition for skin (such as a film-type skin protectant or a film-type skin topical agent) that does not contain a lower monohydric alcohol such as ethanol or isopropanol, is excellent in quick-drying properties and water resistance, is less sticky, and is excellent in feeling of use. The present invention relates to a film-forming composition for skin which contains a specific acrylic polymer, a plasticizer and water and is substantially free of a lower monohydric alcohol such as ethanol or isopropanol. The composition of the present invention is extremely useful for treatment of chronic skin diseases (that is, skin diseases in which skin barrier function is deteriorated) represented by hand eczema, atopic dermatitis, and the like.
Provided are a novel anti-HSV monoclonal antibody, etc. The anti-HSV monoclonal antibody or an antigen-binding fragment thereof that specifically binds to the envelope glycoprotein of herpes simplex virus (HSV), wherein: (i) the heavy chain variable region contains (a) the amino acid sequence of heavy chain CDR1 containing the amino acid sequence of SEQ ID NO: 2, (b) the amino acid sequence of heavy chain CDR2 containing the amino acid sequence of SEQ ID NO: 3, and (c) the amino acid sequence of heavy chain CDR3 containing the amino acid sequence of SEQ ID NO: 4, and (ii) the light chain variable region contains (a) the amino acid sequence of light chain CDR1 containing the amino acid sequence of SEQ ID NO: 6, (b) the amino acid sequence of light chain CDR2 containing the amino acid sequence of SEQ ID NO: 7, and (c) the amino acid sequence of light chain CDR3 containing the amino acid sequence of SEQ ID NO: 8; or (i) the heavy chain variable region contains (d) the amino acid sequence of heavy chain CDR1 containing the amino acid sequence of SEQ ID NO: 12, (e) the amino acid sequence of heavy chain CDR2 containing the amino acid sequence of SEQ ID NO: 13, and (f) the amino acid sequence of heavy chain CDR3 containing the amino acid sequence of SEQ ID NO: 14, and (ii) the light chain variable region contains (d) the amino acid sequence of light chain CDR1 containing the amino acid sequence of SEQ ID NO: 16, (e) the amino acid sequence of light chain CDR2 containing the amino acid sequence of SEQ ID NO: 17, and (f) the amino acid sequence of light chain CDR3 containing the amino acid sequence of SEQ ID NO: 18.
In one embodiment, the present disclosure provides pharmaceutical compositions for suppressing the progression of fibrosis in systemic sclerosis, which contain an antibody against IL-31 receptor A as an active ingredient. In another embodiment, the present disclosure provides pharmaceutical compositions for suppressing Th2 polarization to suppress the progression of fibrosis in systemic sclerosis, which comprise an antibody against IL-31 receptor A as an active ingredient. In a certain embodiment, the above-mentioned antibody is an antibody having a neutralizing activity against IL-31 receptor A.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention provides a novel ophthalmic composition. The ophthalmic composition comprises polysulfated chondroitin sulfate as an active ingredient thereof. This composition is effective for preventing and/or treating keratoconjunctive disorder, and/or for increasing the amount of tear liquid, and/or for preventing or treating dry eye.
The present invention provides a novel therapeutic or prophylactic agent for psoriasis. This therapeutic or prophylactic agent for psoriasis comprises a serotonin-4 receptor agonist.
Provided is an indicator for a measurement device that, in a measurement device for measuring human skin properties, can display the degree of progression of states of at least two types. According to the present invention, provided is an indicator disposed in a measurement device that comprises a housing, a measurement assistance unit slidably supported by the housing, and a sensor part slidably supported by the measurement assistance unit, wherein: the indicator includes a window section formed in a side surface section of the housing, a first display section that is slidably supported in the interior of the window section and is connected to the measurement assistance unit, and a second display section that is slidably supported in the interior of the window section and is connected to the sensor part; the direction of sliding and the amount of sliding of the first display section match the direction of sliding and the amount of sliding of the measurement assistance unit; and the direction of sliding and the amount of sliding of the second display section match the direction of sliding and the amount of sliding of the sensor part.
Provided is a skin condition measurement device capable of measuring human skin conditions in an accurate and stable manner with good reproducibility. The present invention provides a skin condition measurement device including: a housing; a base part that is secured to the interior of the housing; a slider part that is supported by the housing in a slidable manner; a sensor unit that is supported by the slider part in a slidable manner; a first biasing means for biasing the sensor unit so that a distal-end section of the sensor unit is separated from the slider part; a cover part that is connected to the slider part in a detachable manner and that has a guide surface to be pressed against a skin and an opening that is formed in the guide surface and through which the distal-end section of the sensor unit is moved in and out; and a second biasing means for biasing the slider part so that the guide surface is separated from the housing, wherein the skin condition measurement device is configured so that, initially, only the guide surface is moved toward the housing with the guide surface being pressed against the skin in an increasing manner and, subsequently, the guide surface and the distal-end section of the sensor unit are moved toward the housing.
Provided is a skin composition which can reduce side effects of skin drying caused due to benzoyl peroxide and can keep benzoyl peroxide stable. An emulsion topical composition for skin, containing: (A) benzoyl peroxide; (B) 0.3 to 12.5 wt. % of at least one liquid oil having an α value of 0° to 8°; (C) 0.3 to 2.5 wt. % of at least one solid oil; (D) at least one aqueous solvent; and (E) at least one surfactant.
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Provided is a novel composition for treating ringworm. This composition for treating ringworm contains at least one selected from the group consisting of a bacterial strain of Staphylococcus hominis, a bacterial strain of Staphylococcus haemolyticus, and a bacterial strain of Staphylococcus warneri.
The present invention relates to a film-forming skin composition containing (a1) an ethyl acrylate-methyl methacrylate-trimethylammonium ethyl methacrylate chloride copolymer, and (a2) an ethyl acrylate-methyl methacrylate copolymer. The film formed from the composition of the present invention has high water resistance and/or high friction resistance. Meanwhile, this film can be easily washed off from the skin.
A device can pierce and hold tissue and then pass suture through tissue. The device can have a shuttle that can removably attach to a suture and jaws that can be rotatably opened and closed with respect to each other. A method for using the device to repeatedly pass the suture through the tissue without removing the suture or device from the target site is also disclosed.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
16.
INFORMATION PROCESSING DEVICE, COMPUTER PROGRAM, AND INFORMATION PROCESSING METHOD
Provided are an information processing device, a computer program, and an information processing method which can recommend optimal cosmetics to a user. The information processing device comprises: an acquisition unit which acquires counseling information including an answer pertaining to skin concerns of a user; a first selection unit which selects a first cosmetic candidate on the basis of the acquired counseling information; a storage unit which stores association information that associates cosmetics with the skin concerns by using prescribed evaluation indexes; a second selection unit which selects a second cosmetic candidate on the basis of the skin concerns of the user and the association information included in the acquired counseling information; and a recommendation unit which recommends the cosmetics to the user on the basis of the first cosmetic candidate and the second cosmetic candidate.
The present invention addresses the problem of providing a pharmaceutical composition that is for local use and that is appropriate for the alleviation of pain in the oral cavity and/or the pharynx. This pharmaceutical composition for local use contains N,N-dimethyl-2-oxo-N-(2-oxo-2-(phenylamino)ethyl)-2-(phenylamino)ethan-1-aminium and/or a pharmaceutically acceptable salt thereof as the active ingredient. Preferably the pharmaceutical composition contains at least one selected from the group consisting of hydrochloric acid, lactic acid, tartaric acid, and C4 or higher sugar alcohols.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
The present invention provides a novel MMP activity inhibitor and/or production suppressant. The matrix metalloproteinase (MMP) activity inhibitor and/or production suppressant contains benzoyl peroxide. Further provided is a therapeutic agent for acne scars that contains benzoyl peroxide.
A device is disclosed that can pierce and hold tissue and then pass suture through tissue. The device can have a shuttle that can removably attach to a suture and jaws that can be rotatably opened and closed with respect to each other. A method for using the device to repeatedly pass the suture through the tissue without removing the suture or device from the target site is also disclosed.
A61B 17/04 - Surgical instruments, devices or methods for closing wounds or holding wounds closedAccessories for use therewith for suturing woundsHolders or packages for needles or suture materials
A61B 17/06 - NeedlesHolders or packages for needles or suture materials
A deformed nail correction tool (1) comprises: a pair of engagement parts (11) which are each formed from a wire material bent into an arc and at least an arc portion (11a) of which engages with the underside of the tip of a deformed nail when the deformed nail correction tool (1) is fitted onto the deformed nail; and a main body part (12) which has a wave-shaped spring (12a) that is formed by bending the wire material into a wave shape, and both ends of which in the extension direction are continuous with a respective one of the pair of engagement parts (11). The pair of engagement parts (11) and facing parts (12b) of the main body part (12), which face the engagement parts (11) at the side more toward the center than both ends that are continuous with a respective one of the pair of engagement parts (11), sandwich the tip of the deformed nail.
Provided is an external preparation that exhibits a strong clinical effect in patients with severe rosacea. The external preparation is for treatment of at least one skin lesion selected from the group consisting of maculopapule, pustules, and erythema, and contains metronidazole. The external preparation is indicated in patients with severe rosacea, and is applied at the affected site twice daily.
The present invention relates to a nasal polyps reducing agent containing a polysaccharide selected from a polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin and xylo-oligosaccharide, or a salt thereof as an active ingredient, a pharmaceutical composition, a method for reducing nasal polyps or a method for preventing/treating nasal polyps. According to the present invention, it is possible to provide an effective and safe nasal polyps reducing agent.
A61K 31/715 - Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkagesDerivatives thereof, e.g. ethers, esters
What is aimed at is to provide a topical preparation that contains tacrolimus as an active pharmaceutical ingredient, has high stability and transdermal absorbability of the active pharmaceutical ingredient, is less irritating, and has a good feeling of use. The present invention relates to a liquid topical preparation that contains (i) tacrolimus, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and (ii) at least one ketone, and that is substantially free of ethanol. It is preferable that the liquid topical preparation further contains at least one fatty acid ester and fluid paraffin, and is substantially free of water.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/08 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
The present invention addresses the problem of providing a new pharmaceutical composition that can treat a T cell-independent reaction or an early phase reaction (a symptom in an early phase) of an allergic disease. Examples of the present invention include a pharmaceutical composition that contains tacrolimus in an effective amount and that is for treating a T cell-independent allergic disease and/or symptom, a pharmaceutical composition for treating a T cell-independent allergic disease and/or symptom in which ILC2s are activated, and a pharmaceutical composition for treating a T cell-independent allergic disease and/or symptom in which the release and/or production of IL-33 is increased. The present invention can be used for treating an early phase reaction (reaction in an early phase) of an allergic disease and/or symptom or a T cell-independent allergic disease and/or symptom. The present invention is also useful as an ILC2 inactivating agent and an IL-33 inhibitor.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 9/48 - Preparations in capsules, e.g. of gelatin, of chocolate
A61K 9/72 - Medicinal preparations characterised by special physical form for smoking or inhaling
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
A61K 31/46 - 8-Azabicyclo [3.2.1] octaneDerivatives thereof, e.g. atropine, cocaine
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07D 451/10 - Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
C07D 453/02 - Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
C07H 15/04 - Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of a saccharide radical
C07J 5/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, and substituted in position 21 by only one singly bound oxygen atom
Provided is a composition for skin in which it is possible to reduce the adverse effect of skin dryness caused by benzoyl peroxide and to keep the benzoyl peroxide stable. An emulsion composition for external use for skin, the emulsion composition containing (A) benzoyl peroxide, (B) 0.3-12.5 wt% of at least one liquid oil having an α value of 0-8°, (C) 0.3-2.5 wt% of at least one solid oil, (D) at least one aqueous solvent, and (E) at least one surfactant.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
In one embodiment, the present disclosure provides a pharmaceutical composition for suppressing the fibrosis progression in systemic scleroderma, the pharmaceutical composition containing an antibody against IL-31 receptor A as an active ingredient. In another embodiment, the present disclosure provides a pharmaceutical composition for suppressing Th2 bias, the chemical composition: for suppressing fibrosis progression in systemic scleroderma; and containing an antibody against IL-31 receptor A as an active ingredient. In a specific embodiment, the antibody has a neutralization activity against IL-31 receptor A.
[Problem] To provide a composition that can mature or stabilize blood vessels. [Solution] This composition contains pentosan polysulfate and/or a salt thereof as an active ingredient, and is useful for treating and/or preventing diseases associated with vascular lesions and/or lymphatic lesions, or for improving the state of the skin by improving vascular function and/or lymphatic function.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
In one embodiment, the present disclosure provides a pharmaceutical composition for inhibiting the progression of fibrosis in systemic scleroderma, said pharmaceutical composition comprising an antibody against IL-31 receptor A as an active ingredient. In another embodiment, the present disclosure provides a pharmaceutical composition for suppressing a Th2 bias to inhibit the progression of fibrosis in systemic scleroderma, said pharmaceutical composition comprising an antibody against IL-31 receptor A as an active ingredient. In a specific embodiment, the aforesaid antibody is an antibody having a neutralization activity against IL-31 receptor A.
It is an object of the present invention to provide a film-forming composition for skin (such as a film-type skin protectant or a film-type skin topical agent) that does not contain a lower monohydric alcohol such as ethanol or isopropanol, is excellent in quick-drying properties and water resistance, is less sticky, and is excellent in feeling of use. The present invention relates to a film-forming composition for skin which contains a specific acrylic polymer, a plasticizer and water and is substantially free of a lower monohydric alcohol such as ethanol or isopropanol. The composition of the present invention is extremely useful for treatment of chronic skin diseases (that is, skin diseases in which skin barrier function is deteriorated) represented by hand eczema, atopic dermatitis, and the like.
The present invention relates to a membrane forming skin composition that contains (a1) an ethyl acrylate-methyl methacrylate-trimethyl ammonium ethyl chloride methacrylate copolymer, and (a2) an ethyl acrylate-methyl methacrylate copolymer. Membranes formed from this composition have excellent water resistance and are easy to wash off of the skin.
The present invention pertains to a film-forming skin composition that comprises (a1) an ethyl acrylate-methyl methacrylate-trimethylammonium chloride ethyl methacrylate copolymer and (a2) an ethyl acrylate-methyl methacrylate copolymer. A film formed from the composition according to the present invention has high waterproofness and/or high friction resistance. Meanwhile, this film can be easily washed off from the skin.
Tissue care devices and methods of using the same are disclosed. The tissue care devices can have one or multiple expanded configurations and one or multiple contracted configurations. The tissue care devices can be expandable and/or contractible. The tissue devices can have an increasable and/or decreasable outer perimeter.
Provided is a composition that is able to mature blood vessels or stabilize blood vessels. This composition contains a mucopolysaccharide polysulfate and/or a salt thereof as an active ingredient and is useful in treatment and/or prevention of diseases with vascular lesions or lymphatic lesions. The above problem is solved by this composition.
Surgical and medical apparatus and instruments for medical, dental or veterinary use; Orthopedic articles, namely, orthopedic joint implants made of artificial materials and orthopedic devices for diagnostic and therapeutic use; Suture materials
The purpose of the present invention is to provide a safe, effective agent for improving skin texture. It was discovered that a pharmaceutical composition having a polysulfated mucopolysaccharide such as a heparinoid, etc., or a salt thereof as an active ingredient is useful for improving skin texture or shrinking a bumpy area.
The present invention pertains to: a nasal polyp shrinking agent having as an active ingredient a polysaccharide selected from polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin, and xylooligosaccharide, or a salt thereof; a pharmaceutical composition; a nasal polyp shrinking method; or a method for preventing/treating nasal polyps. The present invention can provide a safe, effective nasal polyp shrinking agent.
The present invention addresses the problem of providing a coating-type skin protective agent or a coating-type skin topical agent that does not contain a lower monohydric alcohol such as ethanol and isopropanol, that has excellent quick-drying ability and water resistance, and that is less sticky and provides an excellent sensation when being used. The present invention pertains to a coating-type skin protective agent or a coating-type skin topical agent characterized by containing a water-insoluble polymer, a plasticizing agent, and water, but substantially not containing a lower monohydric alcohol such as ethanol and isopropanol. The skin composition according to the present invention is extremely useful in treating diseases in which skin barrier function is reduced, such as chronic skin diseases represented by hand eczema, atopic dermatitis, and the like.
A61K 8/81 - Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
Provided is a novel compound capable of inhibiting a bond between a BET protein and acetylated lysine. The present invention relates to, for example, the compound represented by general formula (1) or a salt thereof, and a pharmaceutical composition containing said compound as an active ingredient. (In the formula, R1is H, a lower alkyl, or the like. R2is H or a lower alkyl. R3is an aryl that may be substituted, or the like. R4is H, a lower alkyl that may be substituted, a heterocyclic group that may be substituted, or the like. X1, X2, and X3 are C or N. A double line of a solid line and a dotted line represents a single bond or a double bond.) The compound according to the present invention is effective in treating cancer, non-cancerous proliferative diseases, and the like.
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4709 - Non-condensed quinolines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
The present invention addresses the problem of providing a coating-forming-type skin composition (coating-type skin protective agent, coating-type skin topical agent, or the like) that does not contain a lower monovalent alcohol such as ethanol and isopropanol, that has excellent quick-drying ability and water resistance, and that is less sticky and provides excellent sensation when being used. The present invention pertains to a coating-forming-type skin composition characterized by containing a specific acrylic polymer, a plasticizing agent, and water, but substantially not containing a lower monovalent alcohol such as ethanol and isopropanol. The composition according to the present invention is extremely useful in the therapy of chronic skin diseases, etc., represented by hand eczema, atopic dermatitis, or the like (i.e., skin diseases with reduced skin barrier function).
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
The present invention provides methods for the treatment of papulopustular rosacea, including severe papulopustular rosacea, comprising administering a therapeutically effective amount of omiganan or a pharmaceutically acceptable salt thereof.
The present invention addresses the problem of providing a topical preparation s a main ingredient, exhibiting good stability of the main ingredient and high percutaneous absorption, having minimal irritating properties and being pleasant to use. More specifically, provided is a liquid preparation for external use characterized by containing (i) tacrolimus, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof and (ii) at least one kind of ketone, and by not containing substantial amount of ethanol. Preferably, said liquid preparation for external use further contains at least one kind of fatty acid ester and a liquid paraffin, and not contain substantial amount of water.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
The present invention addresses the problem of providing a topical preparation containing tacrolimus as a main ingredient, exhibiting good stability of the main ingredient and high percutaneous absorption, having minimal irritating properties, and being pleasant to use. More specifically, provided is a liquid preparation for external use characterized by containing (i) tacrolimus, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof and (ii) at least one kind of ketone, and by not containing a substantial amount of ethanol. Preferably, said liquid preparation for external use further contains at least one kind of fatty acid ester and a liquid paraffin, and does not contain a substantial amount of water.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
An object of the present invention is mainly to provide a medical skin external preparation that is suitable for treating superficial skin infections, in particular, superficial skin infections accompanied by blister or erosion, etc. For example, the present invention can provide a medical skin external preparation containing 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and an alcohol and/or a fatty acid having 12 or more carbon atoms.
Provided is a skin composition for external use that has skin barrier function-enhancing effects. This skin composition for external use comprises pentosan polysulphate and/or a salt thereof as an active ingredient. The skin composition for external use is useful for preventing and/or treating diseases selected from the group consisting of atopic dermatitis, psoriasis, asteatotic eczema, hand eczema, ichthyosis, and rosacea.
Provided is a topical dermatological composition having an inhibitory effect on collagen and fibronectin production. This topical dermatological composition contains pentosan polysulfate and/or a salt thereof as an active ingredient. This topical dermatological composition is useful in the prevention and/or treatment of conditions such as hypertrophic scars, scars/keloids, muscular torticollis, and nodular eruptions, and exhibits a better inhibitory effect on collagen and fibronectin production than mucopolysaccharide polysulfate (MPS).
Provided is an external composition for skin which has an effect of increasing skin blood flow. The external composition for skin according to the present invention comprises pentosan polysulfuric acid and/or a salt thereof as an active ingredient. This external composition for skin is useful for preventing and/or treating a disease selected from the group consisting of pain and an inflammatory disease induced by hematogenous disorder, chilblains, progressive endocrine keratoderma, and posttraumatic tumentia, hematoma, tenosynovitis, muscle pain and arthritis.
The purpose of the present invention is to provide a pharmaceutical composition that contains 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinoline carboxylic acid and/or a pharmaceutically acceptable salt thereof, the composition being characterized by having an anti-inflammatory effect on dermal inflammation caused by microorganisms. The present invention pertains to, for example, a pharmaceutical composition which contains 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinoline carboxylic acid and/or a pharmaceutically acceptable salt thereof, the composition being characterized by having an anti-inflammatory effect on dermal inflammation caused by microorganisms.
[Problem] The purpose of the present invention is to provide a coating-forming topical agent that suppresses adhesion to clothing, etc., by forming a comfortable coating immediately after application and that also has a sustained medicinal effect. [Solution] Provided is an oil-in-water emulsion-type coating-forming topical agent that contains a medicinal ingredient and also contains an acid of a long-chain hydrocarbon, an alcohol of a long-chain hydrocarbon, an ester of a long-chain hydrocarbon, and/or a salt of these.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
[Problem] The main purpose of the present invention is to provide an external preparation for the skin, characterized by being able to enhance insensible perspiration that is a type of perspiration which can moisturize the skin. [Solution] As an embodiment of the present invention, an external preparation for the skin can be mentioned, which is characterized by containing oversulfated chondroitin sulfate as an active ingredient and capable of being administered to the skin to enhance insensible perspiration.
This deformed nail corrector 1A is designed to correct a deformed nail, and characterized by being provided with a first hook 2, a second hook 3, a pipe-like flexible member 4 which is joined at one end to the first hook 2 and at the other end to the second hook 3, and a wire member 5 which is inserted into the flexible member 4 and has superelastic properties, and in that the flexible member 4 is stretchable so as to allow the distance between the first hook 2 and second hook 3 to be changed.
The purpose of the present invention is mainly to provide a medical skin external preparation that is suitable for treating superficial skin infections, in particular, superficial skin infections accompanied by blisters or erosions and the like. The present invention may provide a medical skin external preparation containing 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and containing an alcohol and/or a fatty acid having 12 or more carbon atoms.
Provided is a transfer-printing method for polyester-based fibrous materials, which requires a small number of steps, which achieves a low fixed cost and a low variable cost, in which a waste water load is small, and with which an excellent-quality transfer-printed product of a polyester-based fibrous material is obtained, the method being characterized by performing transfer printing through bringing, into close contact with a polyester-based fibrous material, and through pressurizing and heating a transfer-printing paper product obtained by performing printing, by using a non-sublimable disperse dye ink, on a transfer-printing paper sheet obtained by providing, to a base-paper sheet, a sizing agent having a functional group selected from the group consisting of an acidic group, an ester, an ether, an amide, an alkaline metal salt, or an alkaline earth metal salt of the acidic group, and a cationic group, or a sizing agent which is selected from a natural gum glue, a cellulose derivative, and a polysaccharide, and in which a carboxylic acid compound is further blended.
Provided is a pharmaceutical composition for the skin having exceptional main drug stability with no changes in the form of the preparation even when stored at high temperatures, the pharmaceutical composition being an aqueous gel preparation including benzoyl peroxide as an active ingredient. An aqueous gel preparation for the skin, wherein the composition contains 2-3.5% by weight of benzoyl peroxide, 0.4-2.2% by weight of a carboxyvinyl polymer, and a chelating agent such as sodium edetate.
Provided is a pharmaceutical composition for the skin having exceptional main drug stability with no changes in the form of the preparation even when stored at high temperatures, the pharmaceutical composition being a pharmaceutical aqueous gel preparation that includes benzoyl peroxide as an active ingredient. A pharmaceutical aqueous gel preparation for the skin, wherein the composition contains 2-3.5% by weight of benzoyl peroxide, 0.4-1.6% by weight of a carboxyvinyl polymer, and a chelating agent such as sodium edetate.
The present invention aims to provide a cyclosporine external preparation showing improved transdermal absorbability of cyclosporine. The present invention provides an external preparation containing cyclosporine and a ketone.
The present invention addresses the problem of providing a fibrous material printing method whereby it becomes possible to achieve excellent production efficiency and excellent quality by employing a high-speed printing process using an aqueous dye ink that can be used in gravure or flexographic printing and using a sheet of paper or a film as a medium. Provided are: a method for producing printed paper or a printed film, comprising a step of printing a sheet of paper for printing use or a film for printing use with an aqueous dye-based printing ink by a gravure or flexographic printing process, wherein the aqueous dye-based printing ink comprises a dye, a viscosity modifier, an aid, a water-miscible organic solvent and water and has a viscosity (25ºC) falling within a specified range; a textile-printing method comprising closely adhering the printed paper or the printed film onto a fibrous material to transfer the color of the printed paper or the printed film to the fibrous material and to develop the color on the fibrous material; and a fibrous material which is printed by the textile-printing method.
B41M 1/26 - Printing on other surfaces than ordinary paper
D06P 3/00 - Special processes of dyeing or printing textiles or dyeing leather, furs or solid macromolecular substances in any form, classified according to the material treated
D06P 5/00 - Other features in dyeing or printing textiles or dyeing leather, furs or solid macromolecular substances in any form
D06Q 1/12 - Decorating textiles by transferring a chemical agent or a metallic or non-metallic material in particulate or other form, from a solid temporary carrier to the textile
D21H 27/00 - Special paper not otherwise provided for, e.g. made by multi-step processes
61.
EXTERNAL PREPARATION FOR TRANSDERMAL ADMINISTRATION
The purpose of the present invention is to provide an external preparation of ciclosporin, wherein the transdermal absorbency of the ciclosporin has been improved. The present invention provides an external preparation that includes ciclosporin, ethanol and a fatty acid monoester.
Provided is a formulation including a vitamin D3 compound and a corticosteroid as active ingredients, wherein the pharmaceutical composition for the skin has exceptional stability of each of the active ingredients and suitable percutaneous absorptivity of the active ingredients. The present invention provides a non-aqueous composition for the skin, wherein the composition contains (a) maxacalcitol, (b) at least one corticosteroid selected from the group consisting of betamethasone and esters thereof, (c) at least one low-polarity ester oil having an IOB value from 0.07 to less than 0.20, and (d) at least one non-polar liquid solvent.
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
Provided is an adapalene-containing composition, for skin, not likely to cause any side effects such as dry skin or the like even when used alone. The composition for skin according to the present invention is characterized by comprising (A) adapalene or a salt thereof, and (B) 5-40 wt% of at least one moisturizing component selected from the group consisting of a macrogol having an average molecular weight of 4000 or less, glycerin, and 1,3-butylene glycol. As the moisturizing component, a macrogol having an average molecular weight of 190-1600 and 1,3-butylene glycol are particularly preferable.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The purpose of the present invention is to provide an external preparation which exerts a therapeutic and/or prophylactic effect on infectious diseases in the field of dermatology such as acne accompanied by suppurative inflammation or epidermal skin infectious diseases when administered once a day mainly to a human patient. As an example of the external preparation according to the present invention, an external preparation, which is characterized by comprising as an active ingredient 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolincarboxylic acid and/or a pharmaceutically acceptable salt thereof and exerting a therapeutic and/or prophylactic effect on infectious diseases in the field of dermatology when administered once a day to a human patient, can be cited.
The invention provides a composition that can alleviate or treat chronic pruritus (itch) by being applied to a lesion and a method for alleviating or treating chronic pruritus with the composition. The composition of the present invention comprises pregabalin and/or gabapentin in a base containing water. Pregabalin and/or gabapentin preferably exists in the form dissolved in water. Also, the method of the present invention can alleviate or treat pruritus by applying the composition to a lesion having chronic pruritus.
A61K 31/195 - Carboxylic acids, e.g. valproic acid having an amino group
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
Provided are: an ointment base which has an adequate consistency that makes the application easy and which has high physical stability; and an ointment. This ointment base is characterized by comprising vaseline, a fatty acid/dextrin, and a solid fat, the amount of the fatty acid/dextrin being 2-10 parts by weight and the sum of the fatty acid/dextrin and the solid fat being 3-34 parts by weight, per 100 parts by weight of the vaseline. It is especially preferred that the ointment base contains 1 part by weight or more of the solid fat and contains the fatty acid/dextrin and the solid fat in a total amount of 4-27 parts by weight, per 100 parts by weight of the vaseline.
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The purpose of the present invention is to provide a cyclosporine topical agent having improved cyclosporine transdermal absorptivity. The present invention provides a topical agent containing cyclosporine and ketones.
The present invention provides a method of detecting dermatophyte, which does not require a complicated operation such as an enzyme treatment and a heat treatment.
The present invention provides a method of detecting dermatophyte, including a step of extracting a dermatophyte component from a sample with a treatment liquid containing a non-ionic surfactant or a zwitterionic surfactant, and a kit for diagnosing dermatophyte infection, containing a treatment liquid comprising the above surfactant, and an antibody specifically recognizing a dermatophyte component, which are housed in separate containers.
C12Q 1/00 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
G01N 33/567 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent utilising isolate of tissue or organ as binding agent
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
The purpose of the present invention is to provide a pregabalin-containing composition that can produce satisfactory drug efficacy through topical administration. This composition is characterized in that the composition is one for topical application to the skin, the pregabalin is contained in a water-containing base, and the pregabalin content is 0.2-3 wt% with respect to total composition weight. The composition exhibits satisfactory drug efficacy despite the low pregabalin content (3 wt% or less) and the fact that pregabalin is the sole active ingredient. The pregabalin is preferably present in a water-dissolved form, and the form of the composition is preferably a solution lotion, emulsion lotion, spray, gel, water-in-oil type cream, or oil-in-water type cream.
A61K 31/197 - Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
Provided are: a solar cell lead wire with which a solar cell module can be manufactured with high cost performance without deteriorating basic functions needed in solar cell lead wires, such as connection reliability with solar cells; and a method for manufacturing the solar cell lead wire. A solar cell lead wire (10) wherein both the front and rear surfaces of a strip board-like conductive material (12) are coated with a solder plating layer (14) is characterized in that the solder thickness (T1) of a bonding layer (14a), which is a part of the solder plating layer (14), and which is formed on the rear surface side of the strip board-like conductive material (12) and is to be bonded to a solar cell, is within a range of 20-50 μm, and the solder thickness (T2) of a front surface layer (14b) formed on the front surface side of the strip board-like conductive material (12) is within a range of 1-10 μm.
Provided is a deformed nail corrector with which the magnitude of elastic force can be adjusted without expending superfluous expense or effort. A deformed nail corrector (1A) for correcting a deformed nail, wherein the deformed nail corrector (1A) is characterized by being provided with: a first elastic wire (2), one end of which is fixed to one end of the deformed nail in the width direction; a second elastic wire (3), one end of which is fixed to the other end of the deformed nail in the width direction; and a unifying means (4) that unifies the first and second elastic wires (2, 3) and is able to slide along the unified first and second elastic wires (2, 3); the first and second elastic wires (2, 3) entering a state of deformation along the deformed nail in a fitted state where the one end of the first elastic wire (2) is fixed to the one end of the deformed nail in the width direction, the one end of the second elastic wire (3) is fixed to the other end of the deformed nail in the width direction, and the first and second elastic wires (2, 3) are unified by the unifying means (4).
The present invention addresses the problem of providing an external preparation for treating trichophytosis unguium, said preparation comprising an imidazole antifungal agent as a principal agent and having a high solubility of the principal agent and a high nail permeability of the principal agent. The external preparation for treating trichophytosis unguium according to the present invention is characterized by comprising an imidazole antifungal agent, lactic acid, tartaric acid, lauromacrogol and 20 wt% or more of water. In particular, the external preparation preferably comprises 5-25 wt% of lactic acid, 0.5-5 wt% of tartaric acid, 3-25 wt% of lauromacrogol and 20-35 wt% of water. The external preparation preferably comprises lanoconazole and/or luliconazole as the aforesaid imidazole antifungal agent.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Provided is a medical product package in which the humidity can be controlled properly to prevent overdry thereof, and which is suitable for the packaging of a granular composition containing a penem antibiotic. A medicinal product package comprising a bag-type packaging body and a granular composition containing a penem antibiotic as an active ingredient and enclosed in the packaging body, wherein the packaging body comprises a packaging body film that comprises at least one base material layer comprising a thermoplastic resin, an aluminum foil and an adsorption layer all laminated in this order, the adsorption layer is arranged on a side on which the granular composition is to be housed and comprises an outer skin layer, an intermediate layer and an inner skin layer laminated in this order when observed from the aluminum foil side, the intermediate layer comprises an LDPE resin and contains a zeolite having a pore diameter of 1 nm or more at a density of 0.2 to 0.4 mg/cm2, and the inner skin layer comprises an LLDPE resin and has a layer thickness of 20 to 30 μm.
The purpose of the present invention is to provide a tacrolimus-containing pharmaceutical composition which is a creamy preparation for external application having a good sensation upon use and has high main ingredient stability (a high main ingredient residual ratio). The composition according to the present invention is an oil-in-water-type creamy composition characterized by comprising (A) tacrolimus, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, (B) diethyl sebacate and/or diisopropyl sebacate, (C) polyoxyethylene hydrogenated castor oil, (D) a hydrophilic polymer and (E) an anti-oxidative agent.
A61K 31/706 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present invention addresses the problem of providing a composition for the skin, which has excellent texture and feeling of use. The present invention provides an anhydrous composition for the skin, which is characterized in that: (A) 80% by weight or more of the composition is composed of a silicone base; (B) the silicone base contains (b1) a silicone elastomer, (b2) a cyclic volatile methyl siloxane that has 3-6 silicon atoms and (b3) a linear dimethyl polysiloxane and/or a linear methylphenyl polysiloxane; (C) the composition contains an active component that is present in a dispersed or dissolved state; and (D) the composition does not contain a non-silicone thickener.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
Provided is a novel pharmaceutical composition (antipruritic) that is useful for the prevention and treatment of itching in conditions such as dermal pruritus. More specifically, provided is a pharmaceutical composition (antipruritic) for the treatment of itching having as an active ingredient thereof the naphthalene compound represented by formula (I), a hydrate thereof, or pharmaceutically acceptable salt thereof (in the formula, ring A represents a heterocyclic ring having one of the illustrated structures).
A61P 43/00 - Drugs for specific purposes, not provided for in groups
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
The purpose of the present invention is to provide a lotion containing an imidazole-type anti-fungal agent, which exhibits excellent transdermal absorbability of the main ingredient and has hypoallergenicity and a fresh sensation upon application. A lotion containing an imidazole-type anti-fungal agent, and characterized in that the imidazole-type anti-fungal agent has a 90% particle diameter (D90) of 30 μm or less and the lotion is a suspended lotion containing 1,3-butylene glycol and water and does not contains any surfactant or any lower monohydric alcohol.
Provided is an ointment which has excellent drug stability and excellent drug uniformity. The ointment, which comprises 1-5 wt% of 1-[2-[(4S)-4-hydroxy-1,2,3,4-tetrahydroquinolin-1-yl]-4-pyridyl]-2,3-bis(hydroxymethyl)-6,7-dimethoxynaphthalene 3/2 hydrate, 3-7 wt% of a separation inhibitor, 15-50 wt% of a gelled hydrocarbon, a pH controller and 0.05-0.4 wt% of an antioxidant, has excellent drug stability and excellent drug dispersibility. In this ointment, polyoxyethylene (196) polyoxypropylene (67) glycol is preferred as the separation inhibitor, diisopropanolamine is preferred as the pH controller, and dibutylhydroxytoluene is preferred as the antioxidant.
The present invention addresses the problem of providing a dermal composition comprising a polymeric reversed micelle that allows a water-soluble drug to be efficiently encapsulated and that is very safe and superior in transdermal absorbability, and providing a method that can produce the composition in simple steps. The dermal composition comprises a polymeric reversed micelle composed of an amphipathic polymer having a hydrophilic segment and a hydrophobic segment, wherein the polymeric reversed micelle has a configuration in which the hydrophilic segment is the core and the hydrophobic segment is the shell, and a water-soluble drug is enclosed therein. The composition can be produced by mixing an oil phase containing the amphipathic polymer in an oily base agent and an aqueous phase containing the water-soluble drug in an aqueous solvent, or by mixing an oily base agent and an aqueous phase containing the amphipathic polymer and the water-soluble drug in an aqueous solvent.
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
B01J 13/00 - Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided forMaking microcapsules or microballoons
The purpose is to provide a tacrolimus-containing pharmaceutical composition which is a creamy preparation for external application having good feeling upon use and has high stability of the main ingredient contained therein (a high main ingredient residual ratio), and of which the concentration in the skin can be controlled readily. Specifically disclosed is an oil-in-water type creamy composition which is characterized by comprising (A) tacrolimus, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, (B) an oil prepared by mixing (a) a medium-chain fatty acid triglyceride with (b) salicylic acid ethylene glycol and/or diisopropyl sebacate, (C) an emulsifying agent having an HLB value of 12 or more, and (D) a hydrophilic polymer, and is also characterized by having a pH value of 4-7.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The purpose is to provide a tacrolimus-containing pharmaceutical composition which is a creamy preparation for external application having good feeling upon use and has high stability of the main ingredient contained therein (a high main ingredient residual ratio), and of which the concentration in the skin can be controlled readily. Specifically disclosed is an oil-in-water type creamy composition which is characterized by comprising (A) tacrolimus, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable solvate thereof, (B) an oil prepared by mixing (a) a medium-chain fatty acid triglyceride with (b) salicylic acid ethylene glycol and/or diisopropyl sebacate, (C) an emulsifying agent having an HLB value of 12 or more, and (D) a hydrophilic polymer, and is also characterized by having a pH value of 4-7.
A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
The present invention provides a method of detecting dermatophyte, which does not require a complicated operation such as an enzyme treatment and a heat treatment.
The present invention provides a method of detecting dermatophyte, including a step of extracting a dermatophyte component from a sample with a treatment liquid containing a non-ionic surfactant or a zwitterionic surfactant, and a kit for diagnosing dermatophyte infection, containing a treatment liquid comprising the above surfactant, and an antibody specifically recognizing a dermatophyte component, which are housed in separate containers.
Disclosed is a medicinal agent which can thicken an epidermis at a thinned leukoderma-affected area to accelerate pigmentation, thereby treating leukoderma. Also disclosed is a method for thickening an epidermis to accelerate pigmentation. A compound capable of thickening an epidermis (e.g., a therapeutic agent for skin ulcer which has been used for the treatment of burn ulcer, crural ulcer, diabetic ulcer or post-operative ulcer, a therapeutic agent for bedsore) is used to treat leukoderma.
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 31/416 - 1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
A dermal external pharmaceutical composition that excels in feeling at application or after application and that by enhancing of the transdermal absorption of cyclosporine, exerts medicinal benefits at low concentration. There is provided a liquid crystal emulsion-type pharmaceutical composition comprising cyclosporine, a hydrophilic nonionic surfactant, a lipophilic nonionic surfactant, an oil, a fatty acid that is insoluble in the oil at room temperature, a solid higher alcohol that is insoluble in the oil at room temperature and a water-soluble polyhydric alcohol that is immiscible with the oil at room temperature, and a method of treating cutaneous diseases with the use of the pharmaceutical composition.
Disclosed is a stable solid preparation comprising a 4,5-epoxymorphinan derivative or a pharmacologically acceptable acid addition salt thereof as an active ingredient. Specifically disclosed is a stable solid preparation comprising: a 4,5-epoxymorphinan derivative represented by the general formula (I) or a pharmacologically acceptable acid addition salt thereof as an active ingredient; sodium thiophosphate; a sugar or a sugar alcohol; and a hydroxypropylcellulose having a low degree of substitution in an amount of 1 to 30% by weight per unit weight of the total amount of the active ingredient, sodium thiophosphate and the sugar or the sugar alcohol.
A microimplement for insertion in skin surface that ensures high safety, no pain and easy use, and that is less in the quantitative limitation or variety restriction as to functional material, etc., realizing high structure strength, high stability and high machining precision, and that in disposal thereof, is very low in environmental load; a process for manufacturing the microimplement; and a relevant method of assembling sugar material parts. There is provided a microimplement for insertion in skin surface having minute cantilevers of a material soluble into the skin, disposed on an upper edge portion of side face of substrate or on a surface of substrate sheet, wherein each of the cantilevers has roughly a half-split cone configuration and has a given dimension. Further, there are provided a process for manufacturing the above microimplement and a relevant method of assembling sugar material parts.
It is intended to provide a lotion which has the high transdermal absorbability of maxacalcitol, can contain maxacalcitol in a chemically stable state and suffers from little dripping when applied to the head. A basic oil-in-water type emulsion lotion containing 22-oxa-1&agr;,25-dihydroxyvitamin D3, a medium-chain fatty acid triglyceride, a nonionic surfactant and a water-soluble thickener; and a method of treating skin diseases by using the same.
The purpose of the present invention is mainly to provide a medical skin external preparation that is suitable for treating superficial skin infections, in particular, superficial skin infections accompanied by blisters or erosions and the like. The present invention may provide a medical skin external preparation containing 1-cyclopropyl-8-methyl-7-[5-methyl-6-(methylamino)-3-pyridyl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid and/or a pharmaceutically acceptable salt thereof as an active ingredient, and containing an alcohol and/or a fatty acid having 12 or more carbon atoms.
In one embodiment, the present disclosure provides pharmaceutical compositions for suppressing the progression of fibrosis in systemic sclerosis, which contain an antibody against IL-31 receptor A as an active ingredient. In another embodiment, the present disclosure provides pharmaceutical compositions for suppressing Th2 polarization to suppress the progression of fibrosis in systemic sclerosis, which comprise an antibody against IL-31 receptor A as an active ingredient. In a certain embodiment, the above-mentioned antibody is an antibody having a neutralizing activity against IL-31 receptor A.
The present invention pertains to: a nasal polyp shrinking agent having as an active ingredient a polysaccharide selected from polysulfated chondroitin sulfate, chondroitin sulfate, dermatan sulfate, keratan sulfate, heparan sulfate, dextran sulfate, pentosan polysulfate (PPS), chondroitin, glucomannan, inulin, and xylooligosaccharide, or a salt thereof; a pharmaceutical composition; a nasal polyp shrinking method; or a method for preventing/treating nasal polyps. The present invention can provide a safe, effective nasal polyp shrinking agent.
A novel composition for treating ringworm is provided. A composition for treating ringworm, including at least one selected from the group consisting of a strain of Staphylococcus hominis, a strain of Staphylococcus haemolyticus, and a strain of Staphylococcus wameri.
